CNTX vs PEPG
CNTX: Clinical-stage biopharmaceutical company developing T-cell engaging bispecific antibodies to treat solid tumors by redirecting immune cells against cancer cells. PEPG: PepGen is a biotechnology company developing novel oligonucleotide therapies that use proprietary peptide-based delivery technology to treat severe neuromuscular and neurological diseases.
Side-by-side fundamentals
| Metric | CNTX | PEPG | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $0.622 | $1.78 | |
| Market cap as of 2026-08-01 | $56M | $123M | |
| PEG as of 2026-08-01 | -0.06 | n/a | |
| ROE as of 2026-08-01 | -60.0% | -59.9% | PEPG higher |
| ROA as of 2026-08-01 | -54.8% | -49.6% | PEPG higher |
| Debt / equity as of 2026-08-01 | 0.00 | 0.00 | Tie |
| Beta as of 2026-08-01 | 1.77 | 1.87 | |
| 1-year return as of 2026-07-27 close | -26.0% | +29.0% | PEPG higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.